<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.aacijournal.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Allergy, Asthma &amp; Clinical Immunology - Latest Articles</title>
        <link>http://www.aacijournal.com</link>
        <description>The latest research articles published by Allergy, Asthma &amp; Clinical Immunology</description>
        <dc:date>2013-06-14T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/22" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/21" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/20" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/19" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/18" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/3" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/17" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/16" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/15" />
                                <rdf:li rdf:resource="http://www.aacijournal.com/content/9/1/14" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.aacijournal.com/content/9/1/22">
        <title>Antibiotic skin testing accompanied by provocative challenges in children is a useful clinical tool</title>
        <description>Background:
Diagnostic testing to antibiotics other than to penicillin has not been widely available, making the diagnosis of antibiotic allergy difficult and often erroneous. There is often reluctance in performing challenges to antibiotics when standardized testing is lacking. However, while the immunogenic determinants are not known for most antibiotics, a skin reaction at a non-irritating concentration (NIC) may mean that antibodies to the native form are present in the circulation. While the NIC&apos;s for many non penicillin antibiotics have been determined in adults, the use of these concentrations for skin testing pediatric subjects prior to provocative challenge has not been done. Our objective was to determine if we could successfully uncover the true nature of antibiotic allergy in children using these concentrations for testing.
Methods:
Children were included between 2003--2009 upon being referred to the Drug and Adverse Reaction/Toxicology (DART) clinic of the Hospital for Sick Children in Toronto, Ontario Canada. The referral needed to demonstrate that clinical care was being compromised by the limitation in antibiotic options or there was a significant medical condition for which the label of antibiotic allergy may prove detrimental. Patients were not seen if there was a suggestion of serum like sickness, Stevens Johnson Syndrome or Toxic Epidermal Necrolysis. Patients were excluded from testing if there was objective evidence of anaphylaxis. All other patients were consented to receive testing and/or challenges. A retrospective chart review was then performed of the results.
Results:
We were able to exclude an antibiotic allergy in the majority of our patients who had a negative intradermal test result and were then challenged (&gt;90%). Only one patient was challenged with a positive intradermal test to Cotrimoxazole because of a questionable history and this patient failed the provocative challenge. While we did not challenge more patients with positive testing, we did note that 10/11 (91%) patients with positive intradermal testing had some aspect of a Type 1 reaction in their history.
Conclusions:
Through testing with NIC&apos;s of various antibiotics in children and providing provocative challenges based on negative skin testing results, we were able to advance the medical care of the majority of our patients by increasing their antibiotic options in order to successfully treat future infections. While challenging patients with positive testing was not deemed ethically appropriate at this stage of our study, it would be a useful future step to reaching statistical validity of testing to these antibiotics.</description>
        <link>http://www.aacijournal.com/content/9/1/22</link>
                <dc:creator>Fotini Kavadas</dc:creator>
                <dc:creator>Anna Kasprzak</dc:creator>
                <dc:creator>Adelle Atkinson</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:22</dc:source>
        <dc:date>2013-06-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-22</dc:identifier>
                                <prism:require>/content/figures/1710-1492-9-22-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2013-06-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/21">
        <title>Ingestion of milk containing the Dp2 peptide, a dust mite allergen, protects mice from allergic airway inflammation and hyper-responsiveness</title>
        <description>Background:
Allergen-specific immunotherapy has been demonstrated to have potential for the treatment of allergic diseases. Transgenic animals are currently the best available bioreactors to produce recombinant proteins, which can be secreted in milk. It has not been clearly demonstrated whether milk from transgenic animals expressing recombinant allergens has immunomodulatory effects on allergic asthma.
Methods:
We aimed to determine whether the oral administration of milk containing a mite allergen can down-regulate allergen-specific airway inflammation. Transgenic CD-1 mice that express a recombinant group 2 allergen from Dermatophagoides pteronyssinus (Dp2) in their milk were generated using an embryonic gene-microinjection technique. Mouse pups were fed transgenic Dp2-containing milk or wild-type milk. Subsequently, these mice were sensitized and challenged with Dp2 to induce allergic airway inflammation.
Results:
Upon sensitization and challenge, mice fed transgenic Dp2 milk had decreased T-helper 2 (Th2) and increased T-helper 1 (Th1) responses in the airway compared with mice fed wild-type milk. Moreover, pre-treatment with transgenic Dp2 milk attenuated airway inflammation and decreased airway hyper-responsiveness.
Conclusions:
This study provides new evidence that oral administration of transgenic milk containing the Dp2 allergen down-regulated and moderately protected against allergic airway inflammation. Milk from transgenic animals expressing allergens may have potential use in the prevention of allergic asthma.</description>
        <link>http://www.aacijournal.com/content/9/1/21</link>
                <dc:creator>Hsu-Chung Liu</dc:creator>
                <dc:creator>Shun-Yuan Pai</dc:creator>
                <dc:creator>Winston Cheng</dc:creator>
                <dc:creator>Hsiao-Ling Chen</dc:creator>
                <dc:creator>Tung-Chou Tsai</dc:creator>
                <dc:creator>Shang-Hsun Yang</dc:creator>
                <dc:creator>Chuan-Mu Chen</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:21</dc:source>
        <dc:date>2013-06-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-21</dc:identifier>
                                <prism:require>/content/figures/1710-1492-9-21-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2013-06-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/20">
        <title>Increase in sensitization to common airborne allergens among adults &#191; two population-based studies 15&#160;years apart</title>
        <description>Background:
Studies on time trends of allergic sensitization among adults are rare. The aim of the study was to compare the prevalence of allergic sensitization to common airborne allergens among adults 15&#160;years apart and to identify risk factors for allergic sensitization.
Methods:
Clinical examinations including skin prick test (SPT) and structured interviews were performed in two random population samples in 1994 and 2009. Furthermore, specific IgE was analyzed in 2009. SPT data were available for 483 subjects in 1994 and for 463 subjects in 2009 in ages 20&#8211;60&#160;years. Specific IgE was analyzed in 692 subjects in ages 20&#8211;79&#160;years.
Results:
Sensitization to cat (16% to 26%, p&#8201;&lt;&#8201;0.001), dog (13% to 25%, p&#8201;&lt;&#8201;0.001), birch (13% to 18%, p&#8201;=&#8201;0.031) and timothy (12% to 21%, p&#8201;&lt;&#8201;0.001), based on SPT, increased significantly from 1994 to 2009. Sensitization to any positive SPT increased from 35% to 39%, p&#8201;=&#8201;0.13.The proportion of having &#8805;3 positive SPT reactions increased from 40% to 56%, p&#8201;=&#8201;0.002. The sensitization pattern yielded similar results based on specific IgE. Risk factors for allergic sensitization were having a family history of allergy (OR 3.1, 95% CI 2.0-4.8 for any positive SPT; OR 2.7, 95% CI 1.8-4.0 for any elevated IgE) and urban living (OR 1.7, 95% CI 1.0-2.7; OR 1.5, 95% CI 1.0-2.4).
Conclusions:
The prevalence of allergic sensitization to major airborne allergens as well as multi-sensitization increased significantly between the study years. Young age, a family history of allergy and urban living were significant risk factors for allergic sensitization.</description>
        <link>http://www.aacijournal.com/content/9/1/20</link>
                <dc:creator>Katja Warm</dc:creator>
                <dc:creator>Anne Lindberg</dc:creator>
                <dc:creator>Bo Lundbäck</dc:creator>
                <dc:creator>Eva Rönmark</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:20</dc:source>
        <dc:date>2013-06-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-20</dc:identifier>
                                <prism:require>/content/figures/1710-1492-9-20-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2013-06-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/19">
        <title>Induction of immune tolerance and reduction of aggravated lung eosinophilia by co-exposure to Asian sand dust and ovalbumin for 14&#160;weeks in mice</title>
        <description>Background:
Atmospheric contamination caused by Asian sand-dust (ASD) storms aggravates asthma in both human adults and children. This study aims to investigate a series of manifestations in allergic airway disease caused by co-exposure to allergens and ASD for 6&#160;weeks and 14&#160;weeks.
Methods:
CD-1 Mice were instilled intratracheally with 0.1&#160;mg of ASD/mouse four times (6&#160;weeks) or eight times (14&#160;weeks) at 2-week intervals (total dose of 0.4&#160;mg or 0.8&#160;mg/mouse) with or without ovalbumin (OVA). The pathologic changes in the airway, cytological alteration in bronchoalveolar lavage fluid (BALF), and levels of inflammatory cytokines/chemokines in BALF, and OVA-specific IgE and IgG1 antibodies in serum were measured in the treated CD-1 mice.
Results:
Four-time co-exposure to OVA and ASD aggravates allergic airway inflammation along with Th2-cytokine IL-13 and eosinophil-relevant cytokine/chemokines IL-5, Eotaxin and MCP-3 in BALF, and fibrous thickening of the subepithelial layer in the airway. On the other hand, eight-time co-exposure attenuates these changes along with a significant increase of TGF-&#946;1 in BALF. Adjuvant effects of ASD toward IgG1 and IgE production in sera were, however, still seen in the eight-time co-exposure.
Conclusions:
These results indicate that the immune responses in airways are exacerbated by four-time co-exposure to ASD with OVA, but that there is a shift to suppressive responses in eight-time co-exposure, suggesting that the responses are caused by TGF-&#946;1-related immune tolerance.</description>
        <link>http://www.aacijournal.com/content/9/1/19</link>
                <dc:creator>Miao He</dc:creator>
                <dc:creator>Takamichi Ichinose</dc:creator>
                <dc:creator>Seiichi Yoshida</dc:creator>
                <dc:creator>Hirohisa Takano</dc:creator>
                <dc:creator>Masataka Nishikawa</dc:creator>
                <dc:creator>Guifan Sun</dc:creator>
                <dc:creator>Takayuki Shibamoto</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:19</dc:source>
        <dc:date>2013-06-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-19</dc:identifier>
                                <prism:require>/content/figures/1710-1492-9-19-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2013-06-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/18">
        <title>Experiencing a first food allergic reaction: a survey of parent and caregiver perspectives</title>
        <description>Background:
Insufficient knowledge of food allergy and anaphylaxis has been identified by caregivers as an important barrier to coping, and a potential cause of fear and anxiety, particularly for those with children newly diagnosed with food allergy.The purpose of the study was to better understand the experiences of caregivers of children with a first allergic reaction to food, and to identify any deficiencies in the information received at diagnosis.
Methods:
A mixed-methods study consisting of an online survey administered to the Anaphylaxis Canada online registry (a patient support group database of approximately 10,000 members), and a follow-up qualitative interview with a subset of survey participants. Analysis consisted of frequency analysis (quantitative and qualitative data) and descriptive statistics to calculate proportions and means with standard deviations. Qualitative analyses were guided by the constant comparative method of grounded theory methodology.
Results:
Of 293 survey respondents, 208 were eligible to complete the survey (first allergic reaction to food within 12&#160;months of the study), and 184 respondents consented. Identified gaps included education about food allergy, anaphylaxis management, for example, how to use epinephrine auto- injectors, and coping strategies for fear and anxiety. The qualitative follow-up study supported these findings, yielding 3 major themes: 1) lack of provision of information following the episode on the recognition and management of food allergy related allergic reactions, 2) prolonged wait times for an allergist, and 3) significant family anxiety.
Conclusions:
The online survey highlighted multiple deficiencies at diagnosis, findings which were supported by the follow up qualitative study. Results will inform the development of educational strategies for patients newly diagnosed with food allergy.</description>
        <link>http://www.aacijournal.com/content/9/1/18</link>
                <dc:creator>Zainab Abdurrahman</dc:creator>
                <dc:creator>Monika Kastner</dc:creator>
                <dc:creator>Cory Wurman</dc:creator>
                <dc:creator>Laurie Harada</dc:creator>
                <dc:creator>Laura Bantock</dc:creator>
                <dc:creator>Heather Cruickshank</dc:creator>
                <dc:creator>Susan Waserman</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:18</dc:source>
        <dc:date>2013-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-18</dc:identifier>
                            <dc:title>Caregivers unsure following first food reaction</dc:title>
                            <dc:description>&lt;p&gt;Parents of children who have an allergic food reaction do not receive sufficient information about allergy management, identifying a reaction, nor anxiety management until referred to an allergist, suggesting improvements are required in first line healthcare.&lt;/p&gt;</dc:description>
                <prism:require>/content/figures/1710-1492-9-18-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2013-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/3">
        <title>Reviewer acknowledgement 2012</title>
        <description>Contributing reviewersThe editors of Allergy, Asthma &amp; Clinical Immunology would like to thank all of our reviewers who have contributed to the journal in Volume 8 (2012).</description>
        <link>http://www.aacijournal.com/content/9/1/3</link>
                <dc:creator>Richard Warrington</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:3</dc:source>
        <dc:date>2013-05-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-3</dc:identifier>
                                <prism:require>/content/figures/1710-1492-9-3-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2013-05-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/17">
        <title>Conducting retrospective impact analysis to inform a medical research charity&#191;s funding strategies: the case of Asthma UK</title>
        <description>Background:
Debate is intensifying about how to assess the full range of impacts from medical research. Complexity increases when assessing the diverse funding streams of funders such as Asthma UK, a charitable patient organisation supporting medical research to benefit people with asthma. This paper aims to describe the various impacts identified from a range of Asthma UK research, and explore how Asthma UK utilised the characteristics of successful funding approaches to inform future research strategies.
Methods:
We adapted the Payback Framework, using it both in a survey and to help structure interviews, documentary analysis, and case studies. We sent surveys to 153 lead researchers of projects, plus 10 past research fellows, and also conducted 14 detailed case studies. These covered nine projects and two fellowships, in addition to the innovative case studies on the professorial chairs (funded since 1988) and the MRC-Asthma UK Centre in Allergic Mechanisms of Asthma (the &#8216;Centre&#8217;) which together facilitated a comprehensive analysis of the whole funding portfolio. We organised each case study to capture whatever academic and wider societal impacts (or payback) might have arisen given the diverse timescales, size of funding involved, and extent to which Asthma UK funding contributed to the impacts.
Results:
Projects recorded an average of four peer-reviewed journal articles. Together the chairs reported over 500 papers. All streams of funding attracted follow-on funding. Each of the various categories of societal impacts arose from only a minority of individual projects and fellowships. Some of the research portfolio is influencing asthma-related clinical guidelines, and some contributing to product development. The latter includes potentially major breakthroughs in asthma therapies (in immunotherapy, and new inhaled drugs) trialled by university spin-out companies. Such research-informed guidelines and medicines can, in turn, contribute to health improvements. The role of the chairs and the pioneering collaborative Centre is shown as being particularly important.
Conclusions:
We systematically demonstrate that all types of Asthma UK&#8217;s research funding assessed are making impacts at different levels, but the main societal impacts from projects and fellowships come from a minority of those funded. Asthma UK used the study&#8217;s findings, especially in relation to the Centre, to inform research funding strategies to promote the achievement of impact.</description>
        <link>http://www.aacijournal.com/content/9/1/17</link>
                <dc:creator>Stephen Hanney</dc:creator>
                <dc:creator>Amanda Watt</dc:creator>
                <dc:creator>Teresa Jones</dc:creator>
                <dc:creator>Leanne Metcalf</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:17</dc:source>
        <dc:date>2013-05-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-17</dc:identifier>
                            <dc:title>Measuring the impact of research funding</dc:title>
                            <dc:description>&lt;p&gt;Health research&amp;nbsp; funded by Asthma UK shows outputs and societal impacts from all types of research funding although the main societal impacts come from a minority of projects . Such assessments help justify research expenditure and inform strategy for future funding.&lt;/p&gt;</dc:description>
                <prism:require>/content/figures/1710-1492-9-17-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2013-05-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/16">
        <title>A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis</title>
        <description>Background:
Azelastine has been shown to be effective against seasonal allergic rhinitis (SAR). The Environmental Exposure Unit (EEU) is a validated model of experimental SAR. The objective of this double-blind, four-way crossover study was to evaluate the onset of action of azelastine nasal spray, versus the oral antihistamines loratadine 10&#160;mg and cetirizine 10&#160;mg in the relief of the symptoms of SAR.
Methods:
70 participants, aged 18-65, were randomized to receive azelastine nasal spray, cetirizine, loratadine, or placebo after controlled ragweed pollen exposure in the EEU. Symptoms were evaluated using the total nasal symptom score (TNSS). The primary efficacy parameter was the onset of action as measured by the change from baseline in TNSS.
Results:
Azelastine displayed a statistically significant improvement in TNSS compared with placebo at all time points from 15&#160;minutes through 6&#160;hours post dose. Azelastine, cetirizine, and loratadine reduced TNSS compared to placebo with an onset of action of 15 (p&#8201;&lt;&#8201;0.001), 60 (p&#8201;=&#8201;0.015), and 75 (p&#8201;=&#8201;0.034) minutes, respectively. The overall assessment of efficacy was rated as good or very good by 46% of the participants for azelastine, 51% of the participants for cetirizine, and 30% of the participants for loratadine compared to 18% of the participants for placebo.
Conclusions:
Azelastine&#8217;s onset of action for symptom relief was faster than that of cetirizine and loratadine. The overall participant satisfaction in treatment with azelastine is comparable to cetirizine and statistically superior to loratadine. These results suggest that azelastine may be preferential to oral antihistamines for the rapid relief of SAR symptoms.</description>
        <link>http://www.aacijournal.com/content/9/1/16</link>
                <dc:creator>Anne Ellis</dc:creator>
                <dc:creator>Yifei Zhu</dc:creator>
                <dc:creator>Lisa Steacy</dc:creator>
                <dc:creator>Terry Walker</dc:creator>
                <dc:creator>James Day</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:16</dc:source>
        <dc:date>2013-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-16</dc:identifier>
                                <prism:require>/content/figures/1710-1492-9-16-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2013-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/15">
        <title>Infant gut microbiota and the hygiene hypothesis of allergic disease: impact of household pets and siblings on microbiota composition and diversity</title>
        <description>Background:
Multiple studies have demonstrated that early-life exposure to pets or siblings affords protection against allergic disease; these associations are commonly attributed to the &#8220;hygiene hypothesis&#8221;. Recently, low diversity of the infant gut microbiota has also been linked to allergic disease. In this study, we characterize the infant gut microbiota in relation to pets and siblings.
Methods:
The study population comprised a small sub-sample of 24 healthy, full term infants from the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort. Mothers reported on household pets and siblings. Fecal samples were collected at 4&#160;months of age, and microbiota composition was characterized by high-throughput signature gene sequencing.
Results:
Microbiota richness and diversity tended to be increased in infants living with pets, whereas these measures were decreased in infants with older siblings. Infants living with pets exhibited under-representation of Bifidobacteriaceae and over-representation of Peptostreptococcaceae; infants with older siblings exhibited under-representation of Peptostreptococcaceae.
Conclusions:
This study provides new evidence that exposure to pets and siblings may influence the early development of the gut microbiota, with potential implications for allergic disease. These two traditionally protective &#8220;hygiene hypothesis&#8221; factors appear to differentially impact gut microbiota composition and diversity, calling into question the clinical significance of these measures. Further research is required to confirm and expand these findings.</description>
        <link>http://www.aacijournal.com/content/9/1/15</link>
                <dc:creator>Meghan Azad</dc:creator>
                <dc:creator>Theodore Konya</dc:creator>
                <dc:creator>Heather Maughan</dc:creator>
                <dc:creator>David Guttman</dc:creator>
                <dc:creator>Catherine Field</dc:creator>
                <dc:creator>Malcolm Sears</dc:creator>
                <dc:creator>Allan Becker</dc:creator>
                <dc:creator>James Scott</dc:creator>
                <dc:creator>Anita Kozyrskyj</dc:creator>
                <dc:creator>CHILD Study Investigators </dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:15</dc:source>
        <dc:date>2013-04-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-15</dc:identifier>
                            <dc:title>Do pets and siblings impact allergic disease?</dc:title>
                            <dc:description>&lt;p&gt;Exposure to pets or siblings differentially affect infant gut microbiota, calling into question the clinical significance of these two traditionally protective &quot;hygiene hypothesis&quot; factors in allergic disease.&lt;/p&gt;</dc:description>
                <prism:require>/content/figures/1710-1492-9-15-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2013-04-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.aacijournal.com/content/9/1/14">
        <title>Confounding with familial determinants affects the association between mode of delivery and childhood asthma medication &#191; a national cohort study</title>
        <description>Background:
Mode of delivery may affect the risk of asthma but the findings have not been consistent and factors shared by siblings may confound the associations in previous studies.
Methods:
The association between mode of delivery and dispensed inhaled corticosteroid (ICS) (a marker of asthma) was examined in a register based national cohort (n=199 837). A cohort analysis of all first born children aged 2-5 and 6-9&#160;years was performed. An age-matched sibling-pair analysis was also performed to account for shared genetic and environmental risk factors.
Results:
Analyses of first-borns demonstrated that elective caesarean section was associated with an increased risk of dispensed ICS in both 2-5 (adjusted odds ratio (aOR)=1.19, 95% confidence interval (CI) 1.09-1.29) and 6-9 (aOR=1.21, 1.09-1.34) age groups. In the sibling-pair analysis, the increased risk associated with elective caesarean section was confirmed in 2-5&#160;year olds (aOR=1.22, 1.05-1.43) but not in 6-9&#160;year olds (aOR=1.06, 0.78-1.44). Emergency caesarean section and vacuum extraction had some association with dispensed ICS in the analyses of first-borns but these associations were not confirmed in the sibling-pair analyses.
Conclusions:
Confounding by familial factors affects the association between mode of delivery and dispensed ICS. Despite this confounding, there was some evidence that elective caesarean section contributed to a modestly increased risk of dispensed ICS but only up to five years of age.</description>
        <link>http://www.aacijournal.com/content/9/1/14</link>
                <dc:creator>Lennart Bråbäck</dc:creator>
                <dc:creator>Cecilia Ekéus</dc:creator>
                <dc:creator>Adrian Lowe</dc:creator>
                <dc:creator>Anders Hjern</dc:creator>
                <dc:source>Allergy, Asthma &amp; Clinical Immunology 2013, null:14</dc:source>
        <dc:date>2013-04-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1710-1492-9-14</dc:identifier>
                            <dc:title>Update on delivery method and asthma risk</dc:title>
                            <dc:description>&lt;p&gt;Accounting for familial factors affects previously demonstrated associations between delivery method and asthma, however there is still evidence that elective C-sections contribute to a modestly increased risk of asthma.&lt;/p&gt;</dc:description>
                <prism:require>/content/figures/1710-1492-9-14-toc.gif</prism:require>
                <prism:publicationName>Allergy, Asthma &amp; Clinical Immunology</prism:publicationName>
        <prism:issn>1710-1492</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2013-04-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
